Pulmonary function in stereotactic body radiotherapy with helical tomotherapy for primary and metastatic lung lesions
- 15 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in La radiologia medica
- Vol. 126 (1), 163-169
- https://doi.org/10.1007/s11547-020-01223-w
Abstract
Aims This retrospective study reports outcomes after stereotactic body radiation therapy (SBRT) as delivered by helical tomotherapy (HT) for lung lesions. It promotes a dose escalation program. Methods Histological and/or radiological findings and/or case histories identified 41 primary and 15 metastatic lesions. Thirty patients received 40 Gy in 5 fractions (BED 72 Gy10Gy) and 26 50 Gy in 5 fractions (BED 100Gy10Gy). Primary end point was lung toxicity. Secondary end points were respiratory function, local control and local progression-free survival. Results Acute toxicity developed in 18/56 patients and late toxicity in 8/54. Median FEV-1 variations versus baseline were − 0.5% (range − 16 to + 43%) at 6 months and − 4.00% (range − 42 to + 18%) at 24 months. Median DLCO variations versus baseline were − 1% (range − 38 to + 36%) at 6 months and − 12.2% (range − 48 to + 11%) at 24 months. At 6 months, a significant positive correlation emerged between FEV-1 change and KPS (p = 0.047). At 24 months, a significant negative correlation emerged between FEV-1 change and the ipsilateral lung V5 (p = 0.006). A low baseline DLCO correlated with more marked DLCO worsening at 6 months (p = 0.012). At 24 months, DLCO worsening correlated significantly with the median contralateral lung dose (p = 0.003). At the last checkup, 23 patients were in complete remission, 16 were in partial remission, 5 had stable disease, and 7 were in relapse. Median follow-up was 12 months (range 5–56). Conclusions In patients with lung disease, SBRT, as delivered by HT, was well tolerated and provided good local control.Keywords
This publication has 33 references indexed in Scilit:
- Significance of low-dose radiation distribution in development of radiation pneumonitis after helical-tomotherapy-based hypofractionated radiotherapy for pulmonary metastasesJournal of Radiation Research, 2013
- Stereotactic body radiotherapy for oligometastasesThe Lancet Oncology, 2013
- Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using TomotherapyRadiation Oncology, 2012
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningThe New England Journal of Medicine, 2011
- Comprehensive Analysis of Pulmonary Function Test (PFT) Changes After Stereotactic Body Radiotherapy (SBRT) for Stage I Lung Cancer in Medically Inoperable PatientsJournal of Thoracic Oncology, 2009
- Radiotherapy of lung cancer: Technology meets biology meets multidisciplinarityRadiotherapy and Oncology, 2009
- Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung MetastasesJournal of Clinical Oncology, 2009
- Baseline Pulmonary Function as a Predictor for Survival and Decline in Pulmonary Function Over Time in Patients Undergoing Stereotactic Body Radiotherapy for the Treatment of Stage I Non–Small-Cell Lung CancerInternational Journal of Radiation Oncology*Biology*Physics, 2008
- A motion phantom study on helical tomotherapy: the dosimetric impacts of delivery technique and motionPhysics in Medicine & Biology, 2006
- Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: A noninvasive treatment approach in medically inoperable patientsInternational Journal of Radiation Oncology*Biology*Physics, 2004